Altimmune's Upcoming Engagement with Investors
Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for liver and cardiometabolic diseases, is set to participate in several notable investor conferences. This presents a valuable opportunity for stakeholders to connect with management and learn about the company’s advancements in treatments, including its leading candidate, pemvidutide.
Upcoming Investor Conferences
Wells Fargo Healthcare Conference
One of the key events on Altimmune’s calendar is the Wells Fargo Healthcare Conference, taking place on a Friday in early September. While this conference will only feature one-on-one meetings, it marks a significant occasion for investors to engage directly with the company.
H.C. Wainwright Global Investment Conference
The H.C. Wainwright Global Investment Conference, scheduled for the following week, will include a fireside chat at 8:30 a.m. Eastern Time. This session is expected to attract considerable attention and will be available via webcast. Investors can tune in to this live session to gain insights into Altimmune’s strategic direction and advancements.
Morgan Stanley Global Healthcare Conference
The subsequent Morgan Stanley Global Healthcare Conference will also feature a fireside chat, earlier in the day. This conference represents a prime avenue for Altimmune to showcase its developments and to foster discussions with potential and current investors alike.
About Altimmune
Altimmune is ardently dedicated to crafting novel solutions for liver and metabolic health challenges. The company's flagship product, pemvidutide, plays a crucial role as a GLP-1/glucagon dual receptor agonist aimed at addressing conditions like MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity. This promising therapeutic not only highlights Altimmune's capabilities but also its commitment to improving patient outcomes.
Company Contact Information
For investors and interested parties, the leadership at Altimmune is readily available for inquiries. Interested individuals can reach out to Greg Weaver, Chief Financial Officer, at 240-654-1450 or contact him via email at ir@altimmune.com.
Additionally, for general inquiries regarding investor relations, Lee Roth from Burns McClellan is approachable at 646-382-3403 or at lroth@burnsmc.com.
The media can connect with Jake Robison from Inizio Evoke Comms at 619-849-5383 or at jake.robison@inizioevoke.com for further information.
Frequently Asked Questions
What is Altimmune primarily focused on?
Altimmune focuses on developing peptide-based therapeutics for liver and cardiometabolic diseases, particularly through its lead product candidate, pemvidutide.
When is the Wells Fargo Healthcare Conference taking place?
The Wells Fargo Healthcare Conference will be held on a Friday in early September and will involve one-on-one meetings only.
What significant events are scheduled for the H.C. Wainwright Conference?
The H.C. Wainwright Conference will feature a fireside chat at 8:30 a.m. Eastern Time, accessible via a webcast.
How can investors reach Altimmune for questions?
Investors can contact Greg Weaver, CFO, at 240-654-1450 or via email at ir@altimmune.com for inquiries.
What conditions does pemvidutide target?
Pemvidutide is developed to treat MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity, addressing significant health challenges.
